Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
GILD Stock Chart & Stats
$120.67
-$0.76(-0.84%)
At close: 4:00 PM EST
$120.67
-$0.76(-0.84%)
Day’s Range― - ―
52-Week Range$88.57 - $128.70
Previous CloseN/A
Volume1.95M
Average Volume (3M)5.74M
Market Cap
$149.71B
Enterprise Value$154.88B
Total Cash (Recent Filing)$7.35B
Total Debt (Recent Filing)$24.94B
Price to Earnings (P/E)18.8
Beta0.34
Next Earnings
Feb 10, 2026EPS Estimate
1.86Next Dividend Ex-DateN/A
Dividend Yield2.52%
Share Statistics
EPS (TTM)2.47
Shares Outstanding1,240,679,600
10 Day Avg. Volume3,534,960
30 Day Avg. Volume5,740,027
Financial Highlights & Ratios
PEG Ratio-2.62
Price to Book (P/B)5.96
Price to Sales (P/S)4.01
P/FCF Ratio11.18
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue5.32
Enterprise Value/Gross Profit6.76
Enterprise Value/Ebitda11.33
Forecast
1Y Price Target
$137.88Price Target Upside14.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
HIV Clinical AdvancementPositive phase three ARTISTRY-1 results for bictegravir with lenacapavir met the non-inferiority endpoint and showed good tolerability, supporting a potential regulatory filing and a launch that could reduce pill burden for patients on complex regimens.
PrEP Commercial GrowthAnalyst sets a buy rating based on expectations that strong PrEP sales from Yeztugo will drive revenue and earnings upside and increase confidence in the company's longer-term growth.
Pricing And Reimbursement SupportAn most-favored-nation pricing agreement for legacy HIV drugs and continued payer support for PrEP with low patient copays create a favorable payment backdrop that can sustain prescription uptake and revenue.
Bears Say
Limited Competitive DataExtremely limited patient data and short follow-up from small samples make competitive comparisons uncertain and could prompt investor caution until larger datasets are available.
Oncology Competitive PressureOncology performance faces headwinds as increasing competition in the CAR T cell space could blunt growth prospects for the company's cell therapy franchise.
Valuation And Regulatory RiskAnalyst notes that the stock trades at a discount to peers because concerns about HIV pricing pressure, Medicaid exposure, and patent uncertainty have weighed on investor sentiment.
Gilead Sciences News
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $88.57 and its highest was $128.70 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $149.71B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Feb 10, 2026 which is in 31 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Oct 30, 2025. The company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.132 by $0.338.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.79 which represents an annual dividend yield of 2.52%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 1.86.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,240,679,600 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $2.47 in its last earnings report, beating expectations of $2.132. Following the earnings report the stock price went up 1.139%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in GILD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gilead Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$137.88 (14.26% Upside)
$137.88 (14.26% Upside)
Blogger Sentiment
Bullish
GILD Sentiment 86%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $625.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.15%
12-Months-Change
Fundamentals
Return on Equity
40.53%
Trailing 12-Months
Asset Growth
7.35%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Company Deck
GILD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in the HIV portfolio and successful launches of new products like Yeztugo, boosting revenue expectations despite challenges in oncology and cell therapy segments. The overall sentiment is positive, driven by strong commercial execution and strategic advancements.View all GILD earnings summariesGILD Revenue Breakdown
68.21% HIV
10.51% Liver Disease
6.26% Veklury
11.44% Oncology
3.09% Other
0.50% Royalty, contract and other revenues
GILD Stock 12 Month Forecast
Average Price Target
$137.88
▲(14.26% Upside)
Technical Analysis
Ownership Overview
0.09% Insiders
29.15% Mutual Funds
18.26% Other Institutional Investors
25.14% Public Companies and Individual Investors